Traditional Chinese medicine for treating multiple sclerosis

Abstract

The invention relates to the field of traditional Chinese medicine application and particularly discloses a traditional Chinese medicine for treating multiple sclerosis. The traditional Chinese medicine for treating multiple sclerosis is prepared from raspberries, agalma delavayi (Franch.) Hutch., cotton seeds, herb of variegate ladyslipper, rhizomes of whorledleaf solomonseal, melastoma polyanthum, concha arcae, astilboides tabularis, berchemia lineate, begonia palmate, platanthera chlorantha cust. ex Rchb, hygrophila salicifolia, ormosia henryi, all-grass of loureiro clematis, rhizomes of kirilow rhodiola, oxalis corniculata, isodon japonica var.galaucocalyx, licorice roots, radix geutianae, bile arisaema, purple flower holly leaves, hypericum japonicum, lysimachia fortunei maxim, clerodendron cyrtophyllum turcz., euphorbia hirta, melothria ndica Lour.Zehneria indica (Lour.) C. Y. Wu, pinnated brake herb, scirpus fluviatilis, radix saussureae lappae, stems of common stelmatocrypton and ranunculaceae clematis henryi, and the traditional Chinese medicine materials are mixed and prepared into the traditional Chinese medicine according to a certain weight proportion. The traditional Chinese medicine is easy to prepare, good in absorbing effect, long in medicine effect lasting time, remarkable in curative effect, free of side effects, high in safety and low in production cost, multiple sclerosis will not relapse after medicine withdrawal, and symptoms of patients can be alleviated easily.

Description

(1) Technical field [0001] The invention relates to the field of application of traditional Chinese medicines, in particular to a traditional Chinese medicine for treating multiple sclerosis. (2) Background technology [0002] Multiple sclerosis is an autoimmune disease characterized by inflammatory demyelinating lesions of the white matter of the central nervous system. The main clinical features are the scattered distribution of multiple lesions in the white matter of the central nervous system and remission and recurrence during the course of the disease, the spatial multiple of symptoms and signs and the temporal multiple of the course of the disease. The age of onset is mostly between 20 and 40 years old, and it is rare for patients under 10 years old and over 50 years old. The male to female prevalence ratio is 1:2. The form of onset is mostly subacute onset, and acute and insidious onset are only seen in a few cases. Limb weakness is common in clinical symptoms and ...

AI Technical Summary

Problems solved by technology

At present, there is no effective clinical treatment. Hormones and immunosuppressants are mainly used to inhibit the progress of inflammatory demyelinating lesions. Symptomatic and supportive therapies are used to relieve the pain caused by neurological dysfunction.